Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15189279 | 0.82 | CCR1 (0.43) | PDE10ACCR1CCR5CCR8HDAC6 | |
| SCHEMBL8282593 | 0.82 | CCR1 (0.43) | CCR1CCR5CCR8HDAC6KDM4E | |
| SCHEMBL14294218 | 0.81 | KDM4E (0.39) | PDE10ACCR1CCR5CCR8HDAC6 | |
| SCHEMBL10555554 | 0.80 | CCR1 (0.41) | PDE10ACCR1CCR5CCR8HDAC6 | |
| SCHEMBL20381746 | 0.80 | MAPT (0.44) | CCR1CCR5CCR8HDAC6KDM4E | |
| SCHEMBL832761 | 0.80 | KDM4E (0.44) | PDE10APIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL19732860 | 0.80 | NOS3 (0.43) | CCR1CCR5CCR8HDAC6KDM4E | |
| SCHEMBL20381799 | 0.80 | CCR1 (0.41) | PDE10ACCR1CCR5CCR8HDAC6 | |
| SCHEMBL15489125 | 0.80 | APP (0.43) | CCR1CCR5CCR8HDAC6KDM4E | |
| SCHEMBL10187966 | 0.78 | PIK3CD (0.43) | PDE10APIK3CDPIK3CAPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171440-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019149260-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| WO-2018103688-A1 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | BEIGENE, LTD. (KY) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018049296-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171440-A1 | WRN INHIBITORS | WRN, BLM, RECQL | PDE10A 4015/4885PIK3CD 2752/4885PIK3CA 1856/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | PDE10A 1214/4885PIK3CD 3473/4885PIK3CA 2341/4885 |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | PDE10A 3464/4885PIK3CD 223/4885PIK3CA 340/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDE10A 2958/4885PIK3CD 1998/4885PIK3CA 1181/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | PDE10A 1369/4885PIK3CD 2691/4885PIK3CA 2030/4885 |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | MC4R, MC3R, MC5R | PDE10A 4689/4885PIK3CD 2483/4885PIK3CA 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.